• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小RNA-195抑制人肝癌细胞的致瘤性并调节G1/S期转换。

MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells.

作者信息

Xu Teng, Zhu Ying, Xiong Yujuan, Ge Yi-Yuan, Yun Jing-Ping, Zhuang Shi-Mei

机构信息

Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Guangzhou, PR China.

出版信息

Hepatology. 2009 Jul;50(1):113-21. doi: 10.1002/hep.22919.

DOI:10.1002/hep.22919
PMID:19441017
Abstract

UNLABELLED

Growing evidence indicates that deregulation of microRNAs (miRNAs) contributes to tumorigenesis. Down-regulation of miR-195 has been observed in various types of cancers. However, the biological function of miR-195 is still largely unknown. In this study we aimed to elucidate the pathophysiologic role of miR-195. Our results showed that miR-195 expression was significantly reduced in as high as 85.7% of hepatocellular carcinoma (HCC) tissues and in all of the five HCC cell lines examined. Moreover, introduction of miR-195 dramatically suppressed the ability of HCC and colorectal carcinoma cells to form colonies in vitro and to develop tumors in nude mice. Furthermore, ectopic expression of miR-195 blocked G(1)/S transition, whereas inhibition of miR-195 promoted cell cycle progression. Subsequent investigation characterized multiple G(1)/S transition-related molecules, including cyclin D1, CDK6, and E2F3, as direct targets of miR-195. Silencing of cyclin D1, CDK6, or E2F3 phenocopied the effect of miR-195, whereas overexpression of these proteins attenuated miR-195-induced G(1) arrest. In addition, miR-195 significantly repressed the phosphorylation of Rb as well as the transactivation of downstream target genes of E2F. These results imply that miR-195 may block the G(1)/S transition by repressing Rb-E2F signaling through targeting multiple molecules, including cyclin D1, CDK6, and E2F3.

CONCLUSION

Our data highlight an important role of miR-195 in cell cycle control and in the molecular etiology of HCC, and implicate the potential application of miR-195 in cancer therapy.

摘要

未标记

越来越多的证据表明,微小RNA(miRNA)失调与肿瘤发生有关。在各种类型的癌症中均观察到miR-195表达下调。然而,miR-195的生物学功能仍大多未知。在本研究中,我们旨在阐明miR-195的病理生理作用。我们的结果显示,在高达85.7%的肝细胞癌(HCC)组织以及所有检测的5种HCC细胞系中,miR-195表达均显著降低。此外,导入miR-195可显著抑制HCC和结肠癌细胞在体外形成集落以及在裸鼠体内形成肿瘤的能力。此外,miR-195的异位表达阻断了G(1)/S期转换,而抑制miR-195则促进细胞周期进程。随后的研究鉴定了多个与G(1)/S期转换相关的分子,包括细胞周期蛋白D1、细胞周期蛋白依赖性激酶6(CDK6)和E2F3,作为miR-195的直接靶标。沉默细胞周期蛋白D1、CDK6或E2F3可模拟miR-195的作用,而这些蛋白的过表达则减弱了miR-195诱导的G(1)期阻滞。此外,miR-195显著抑制Rb的磷酸化以及E2F下游靶基因的反式激活。这些结果表明,miR-195可能通过靶向包括细胞周期蛋白D1、CDK6和E2F3在内地多个分子抑制Rb-E2F信号传导,从而阻断G(1)/S期转换。

结论

我们的数据突出了miR-195在细胞周期调控以及HCC分子病因学中的重要作用,并提示miR-195在癌症治疗中的潜在应用。

相似文献

1
MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells.微小RNA-195抑制人肝癌细胞的致瘤性并调节G1/S期转换。
Hepatology. 2009 Jul;50(1):113-21. doi: 10.1002/hep.22919.
2
MicroRNA-503 inhibits the G1/S transition by downregulating cyclin D3 and E2F3 in hepatocellular carcinoma.MicroRNA-503 通过下调肝细胞癌中的细胞周期蛋白 D3 和 E2F3 来抑制 G1/S 期转换。
J Transl Med. 2013 Aug 22;11:195. doi: 10.1186/1479-5876-11-195.
3
MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity.微小RNA-101在肝细胞癌中表达下调,可促进细胞凋亡并抑制肿瘤发生。
Cancer Res. 2009 Feb 1;69(3):1135-42. doi: 10.1158/0008-5472.CAN-08-2886. Epub 2009 Jan 20.
4
Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma.微小 RNA-29 对肝癌细胞凋亡、致瘤性和预后的影响。
Hepatology. 2010 Mar;51(3):836-45. doi: 10.1002/hep.23380.
5
RETRACTED: miRNA-302b suppresses human hepatocellular carcinoma by targeting AKT2.撤回:miRNA-302b 通过靶向 AKT2 抑制人肝癌。
Mol Cancer Res. 2014 Feb;12(2):190-202. doi: 10.1158/1541-7786.MCR-13-0411. Epub 2013 Dec 13.
6
MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.微小 RNA-101 通过下调 EZH2 并增加细胞抑制性药物敏感性抑制人肝癌进展。
J Hepatol. 2014 Mar;60(3):590-8. doi: 10.1016/j.jhep.2013.10.028. Epub 2013 Nov 6.
7
MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3.MicroRNA-125b 通过靶向 E2F3 抑制膀胱癌的发展。
Int J Cancer. 2011 Apr 15;128(8):1758-69. doi: 10.1002/ijc.25509.
8
miR-1299 suppresses cell proliferation of hepatocellular carcinoma (HCC) by targeting CDK6.miR-1299 通过靶向 CDK6 抑制肝癌(HCC)细胞的增殖。
Biomed Pharmacother. 2016 Oct;83:792-797. doi: 10.1016/j.biopha.2016.07.037. Epub 2016 Aug 2.
9
MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway.miRNA-449a 通过 G1 期阻滞和 HGF/MET c-Met 通路抑制肝癌细胞生长。
Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):336-344. doi: 10.1016/j.hbpd.2018.07.006. Epub 2018 Jul 26.
10
MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma.MicroRNA-29c 通过直接靶向肝癌中的致癌 SIRT1 发挥肿瘤抑制作用。
Oncogene. 2014 May 15;33(20):2557-67. doi: 10.1038/onc.2013.216. Epub 2013 Jun 3.

引用本文的文献

1
Clinical implications of miR-195 in cancer: mechanisms, potential applications, and therapeutic strategies.miR-195在癌症中的临床意义:作用机制、潜在应用及治疗策略
J Cancer Res Clin Oncol. 2025 Apr 22;151(4):148. doi: 10.1007/s00432-025-06195-w.
2
miRNAs in HCC, pathogenesis, and targets.肝癌中的微小RNA、发病机制及靶点。
Hepatology. 2024 Nov 29. doi: 10.1097/HEP.0000000000001177.
3
SNHG1: Redefining the Landscape of Hepatocellular Carcinoma through Long Noncoding RNAs.SNHG1:通过长链非编码RNA重新定义肝细胞癌格局
Biomedicines. 2024 Jul 30;12(8):1696. doi: 10.3390/biomedicines12081696.
4
Interaction between microRNA-195 and HuR regulates Paneth cell function in the intestinal epithelium by altering SOX9 translation.微小RNA-195与HuR之间的相互作用通过改变SOX9的翻译来调节肠道上皮中潘氏细胞的功能。
Am J Physiol Cell Physiol. 2024 Sep 1;327(3):C817-C829. doi: 10.1152/ajpcell.00325.2024. Epub 2024 Aug 5.
5
Nanoquercetin and Extracellular Vesicles as Potential Anticancer Therapeutics in Hepatocellular Carcinoma.纳米槲皮素和细胞外囊泡作为肝癌潜在的抗癌治疗方法。
Cells. 2024 Apr 5;13(7):638. doi: 10.3390/cells13070638.
6
Posttranscriptional Regulation of Intestinal Mucosal Growth and Adaptation by Noncoding RNAs in Critical Surgical Disorders.非编码 RNA 在危重症外科疾病中的肠道黏膜生长和适应性的转录后调控。
J Invest Surg. 2024 Dec;37(1):2308809. doi: 10.1080/08941939.2024.2308809. Epub 2024 Feb 7.
7
Circular RNA Cdr1as inhibits proliferation and delays injury-induced regeneration of the intestinal epithelium.环状 RNA Cdr1as 抑制肠道上皮细胞的增殖并延缓损伤诱导的再生。
JCI Insight. 2024 Jan 16;9(4):e169716. doi: 10.1172/jci.insight.169716.
8
miR-195b is required for proper cellular homeostasis in the elderly.miR-195b 是老年人细胞内稳态所必需的。
Sci Rep. 2024 Jan 8;14(1):810. doi: 10.1038/s41598-024-51256-8.
9
A Novel LncRNA MASCC1 Regulates the Progression and Metastasis of Head and Neck Squamous Cell Carcinoma by Sponging miR-195.一种新型长链非编码RNA MASCC1通过吸附miR-195调控头颈部鳞状细胞癌的进展和转移。
Cancers (Basel). 2023 Dec 11;15(24):5792. doi: 10.3390/cancers15245792.
10
Tumor Microenvironment Remodeling in Gastrointestinal Cancer: Role of miRNAs as Biomarkers of Tumor Invasion.胃肠道癌中的肿瘤微环境重塑:微小RNA作为肿瘤侵袭生物标志物的作用
Biomedicines. 2023 Jun 19;11(6):1761. doi: 10.3390/biomedicines11061761.